Combination of Gefitinib With Chemotherapy or Anti-angiogenesis as 1st Line Treatment in Advanced NSCLC Patients Detected With Bim Deletion or Low EGFR Activating Mutation Abundance

NCT02930954 Phase 2 UNKNOWN

This is a single arm phase II clinical trial, which aims to evaluate the effectiveness of combination of gefitinib and doublet chemotherapy or antiangiogenesis in advanced non-small cell lung cancer patients with EGFR activating mutation, accompanied with Bim deletion or low activating EGFR mutation abundance.

Details

Lead sponsor	Caicun Zhou
Phase	Phase 2
Status	UNKNOWN
Enrolment	180
Start date	2016-11
Completion	2018-12

Conditions

• Non-small-cell Lung Cancer

Interventions

• Gefitinib
• pemetrexed or gemcitabine plus carboplatin,
• bevacizumab

Primary outcomes

• Progression free survival — 8 weeks
  From start of anti-cancer therapy untill progression or death

Countries

China